Rifampicin in the retreatment of severe cavitary pulmonary tuberculosis. I. Some considerations on the sputum conversion rate and the emergence of drug resistance.
D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000008:administration & dosage; D004352:Drug Resistance, Microbial; D004977:Ethambutol / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007612:Kanamycin / Q000008:administration & dosage; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use*; D013183:Sputum / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D007612:Kanamycin; D004977:Ethambutol; D012293:Rifampin